W.P. Steward

1.3k total citations
31 papers, 1.0k citations indexed

About

W.P. Steward is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, W.P. Steward has authored 31 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 9 papers in Molecular Biology. Recurrent topics in W.P. Steward's work include Lung Cancer Treatments and Mutations (8 papers), Cancer therapeutics and mechanisms (4 papers) and Cancer Treatment and Pharmacology (4 papers). W.P. Steward is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Cancer therapeutics and mechanisms (4 papers) and Cancer Treatment and Pharmacology (4 papers). W.P. Steward collaborates with scholars based in United Kingdom, Italy and Netherlands. W.P. Steward's co-authors include Jaap Verweij, R. Somers, Armando Santoro, Henning T. Mouridsen, J. Buesa, Paolo G. Casali, T Türsz, Elaine M. Rankin, D. Spooner and A. Gescher and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Cancer.

In The Last Decade

W.P. Steward

31 papers receiving 971 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
W.P. Steward United Kingdom 13 567 502 244 159 148 31 1.0k
Michael A. Levesque Canada 19 407 0.7× 336 0.7× 405 1.7× 220 1.4× 116 0.8× 32 1.2k
Diane Savarese United States 16 576 1.0× 526 1.0× 274 1.1× 184 1.2× 93 0.6× 24 1.2k
Anna Fedeli Italy 17 536 0.9× 369 0.7× 108 0.4× 110 0.7× 58 0.4× 43 939
J. Wendall Goodwin United States 16 522 0.9× 334 0.7× 186 0.8× 102 0.6× 55 0.4× 34 1.0k
Hugh L. Davis United States 19 517 0.9× 276 0.5× 144 0.6× 172 1.1× 180 1.2× 46 1.1k
Adrian Langleben Canada 17 725 1.3× 416 0.8× 316 1.3× 158 1.0× 63 0.4× 55 1.1k
M Soukop United Kingdom 19 575 1.0× 169 0.3× 236 1.0× 111 0.7× 234 1.6× 48 1.1k
Rodolfo Mattioli Italy 17 707 1.2× 306 0.6× 298 1.2× 128 0.8× 145 1.0× 61 995
Dale R. Shepard United States 17 478 0.8× 470 0.9× 419 1.7× 258 1.6× 95 0.6× 75 1.2k
Luigi Di Lauro Italy 25 886 1.6× 307 0.6× 398 1.6× 328 2.1× 213 1.4× 113 1.7k

Countries citing papers authored by W.P. Steward

Since Specialization
Citations

This map shows the geographic impact of W.P. Steward's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W.P. Steward with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W.P. Steward more than expected).

Fields of papers citing papers by W.P. Steward

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W.P. Steward. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W.P. Steward. The network helps show where W.P. Steward may publish in the future.

Co-authorship network of co-authors of W.P. Steward

This figure shows the co-authorship network connecting the top 25 collaborators of W.P. Steward. A scholar is included among the top collaborators of W.P. Steward based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W.P. Steward. W.P. Steward is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Jain, Sunjay, et al.. (2007). A Review of Phase III Clinical Trials of Prostate Cancer Chemoprevention. Annals of The Royal College of Surgeons of England. 89(3). 207–211. 18 indexed citations
3.
Neal, Christopher P., Donald A. Berry, H. Doucas, et al.. (2006). Clinical Aspects of Natural Anti-Angiogenic Drugs. Current Drug Targets. 7(3). 371–383. 10 indexed citations
4.
Sharma, Ricky A., et al.. (2004). Oxidative stress and cyclooxygenase activity in prostate carcinogenesis: targets for chemopreventive strategies. European Journal of Cancer. 41(1). 61–70. 103 indexed citations
5.
Gescher, A., et al.. (2003). ErbB receptors: possible therapeutic targets in prostate cancer?. British Journal of Urology. 92(9). 890–895. 28 indexed citations
6.
Smith, Lucy, et al.. (2003). Latest trends in cancer incidence among UK South Asians in Leicester. British Journal of Cancer. 89(1). 70–73. 46 indexed citations
7.
Levitt, N C, Ferry A.L.M. Eskens, Kenneth J. O’Byrne, et al.. (2001). Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.. PubMed. 7(7). 1912–22. 106 indexed citations
8.
Thomas, Anne & W.P. Steward. (2001). Recent advances in the nonsurgical treatment of upper gastrointestinal tract tumors. Expert Review of Anticancer Therapy. 1(2). 258–268. 3 indexed citations
9.
Steward, W.P.. (1998). Combination studies with gemcitabine in the treatment of non-small-cell lung cancer. British Journal of Cancer. 78(S3). 15–19. 23 indexed citations
10.
Abratt, Raymond P., et al.. (1997). Dose scheduling & drug tolerability in phase II studies of gemcitabine and cisplstin chemotherapy for non-small cell lung cancer. European Journal of Cancer. 33. S236–S237. 1 indexed citations
11.
Viallet, Jean, David J. Stewart, F. Shepherd, et al.. (1996). Tallimustine is inactive in patients with previously treated small cell lung cancer. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. Lung Cancer. 15(3). 367–373. 17 indexed citations
12.
Holyoake, Tessa L., M Freshney, Lindsay McNair, et al.. (1996). Ex vivo expansion with stem cell factor and interleukin-11 augments both short-term recovery posttransplant and the ability to serially transplant marrow. Blood. 87(11). 4589–4595. 73 indexed citations
13.
Steward, W.P. & David J. Dunlop. (1995). New drugs in the treatment of non-small cell lung cancer. Annals of Oncology. 6. S49–S54. 12 indexed citations
14.
15.
Kerbrat, Pierre, R. Somers, Jaap Verweij, et al.. (1993). Phase II study of fotemustine in advanced soft tissue sarcomas. European Journal of Cancer. 29(1). 143–144. 3 indexed citations
16.
Schütte, J., Henning T. Mouridsen, W.P. Steward, et al.. (1993). Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma.. PubMed. 31 Suppl 2. S204–9. 20 indexed citations
17.
Steward, W.P., David B. Smith, & D. Crowther. (1991). Weekly oral 4-demethoxydaunorubicin in patients with relapsed low grade non-Hodgkin's lymphoma. Annals of Oncology. 2(8). 605–606. 8 indexed citations
18.
Steward, W.P., et al.. (1990). Clinical application of hematopoietic growth factors.. PubMed. 49. 359–78. 4 indexed citations
19.
Steward, W.P., et al.. (1988). Phase I study of recombinant DNA granulocyte macrophage colony stimulating factor.. PubMed. 324–6. 6 indexed citations
20.
Steward, W.P., et al.. (1985). Treatment of relapsed non-Hodgkin's lymphoma with a combination of hydroxyurea, ifosfamide, and etoposide.. PubMed. 69(2). 225–6. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael A. Levesque Breakdown of academic impact, for papers by Diane Savarese Breakdown of academic impact, for papers by Anna Fedeli Breakdown of academic impact, for papers by J. Wendall Goodwin Breakdown of academic impact, for papers by Hugh L. Davis Breakdown of academic impact, for papers by Adrian Langleben Breakdown of academic impact, for papers by M Soukop Breakdown of academic impact, for papers by Rodolfo Mattioli Breakdown of academic impact, for papers by Dale R. Shepard Breakdown of academic impact, for papers by Luigi Di Lauro
Rankless by CCL
2026